New drug tested for advanced cancers: early safety check
NCT ID NCT05627063
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This early-phase study tests a new oral drug called ABSK121-NX in about 169 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for any signs that the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89119, United States
-
Fujian Cancer Hospital (Department of Hepatobiliary and Pancreatic Oncology /Phase I Ward)
Fuzhou, China
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
Harbin Medical University Cancer Hospital (Gastroenterology Department 2nd Ward)
Haerbin, China
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Hunan Central Hospital
Changsha, Hunan, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Liaoning Cancer Hospital (Phase I Ward)
Shenyang, China
-
Mianyang Central Hospital
Mianyang, Sichuan, China
-
Shanghai East Hospital Tongji University
Shanghai, Shanghai Municipality, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
West China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Yantai Yuhuangding Hospital (Department of Medical Oncology, 1)
Yantai, China
-
Zhejiang University Cancer Hospital
Hangzhou, Zhejiang, China
-
Zhongshan Hospital of Fudan University (Hepatological Surgery Department)
Shanghai, China
-
Zhongshan Hospital of Fudan University (Medical Oncology Department)
Shanghai, China
Conditions
Explore the condition pages connected to this study.